Abstract Details

Title MRI Characteristics of Chronic MS Lesions by Phase Rim Detection and/or Slowly Expanding Properties

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 139

Objective

To evaluate the colocalization of phase rim lesions (PRLs) and slowly expanding lesions (SELs) and compare normalized magnetization transfer ratio (nMTR) and diffusion tensor imaging radial diffusivity (DTI-RD) in PRLs and SELs in patients with relapsing multiple sclerosis (RMS).

Background

PRLs, as detected on susceptibility-weighted phase images, have been associated with chronic active MS lesions. SELs have been posited as a marker of chronic active MS lesions that can be assessed using only conventional MRI sequences; however, their correspondence with PRLs is unknown.

Design/Methods PRLs were detected at Week 72 in a subset of RMS patients from the AFFINITY trial [] (N=44) using standardized 3-Tesla Siemens 3D isotropic multi-echo Spoiled Gradient T2*. SELs were detected as areas of baseline T2 lesions that showed constant and concentric expansion from baseline to Week 72, using longitudinal T1- and T2-weighted acquisitions.

Results More than twice as many SELs were detected as PRLs. Thirty-seven percent of PRLs (44/118) colocalized with SELs while 16 % (42/267) of SELs colocalized with PRLs. Moderate correlation of SEL and PRL counts across patients was observed (r=0.69). SELs colocalizing with PRLs appeared to be larger in size than those lesions that were PRL+/SEL- or PRL-/SEL+. Chronic lesions that were detected as both PRL+/SEL+ had lowest nMTR and higher DTI-RD, compared to PRL+/SEL- and PRL-/SEL+.

Conclusions

White matter lesions defined as SELs and PRLs show only partial correspondence and only a minority of SELs are associated with phase rims and vice versa. SELs and PRLs that colocalized may represent the most severe subset of chronic active white matter lesions. Ongoing investigations of SELs and PRLs may help to clarify MRI lesion subtypes and lead to more sensitive markers of MS disease progression.

Support: This study is funded by Biogen

Authors/Disclosures
Colm Elliott (NeuroRx Research) PRESENTER	Colm Elliott has received personal compensation for serving as an employee of NeuroRx Research.
Shibeshih Belachew, MD	Dr. Belachew has received personal compensation for serving as an employee of Biogen Inc. Dr. Belachew has received stock or an ownership interest from Biogen Inc.
Elizabeth Fisher	Elizabeth Fisher has received personal compensation for serving as an employee of Biogen. Elizabeth Fisher has stock in Biogen. Elizabeth Fisher has received intellectual property interests from a discovery or technology relating to health care.
Bing Zhu	Bing Zhu has received personal compensation for serving as an employee of Biogen. Bing Zhu has received stock or an ownership interest from Biogen.
Dawei Liu	Dawei Liu has received personal compensation for serving as an employee of Biogen. Dawei Liu has received stock or an ownership interest from Biogen.
Li Zhu	Li Zhu has received personal compensation for serving as an employee of Biogen.
	No disclosure on file
	No disclosure on file
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ)	Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clario.
	No disclosure on file
	No disclosure on file
Daniel P. Bradley	Daniel Bradley has nothing to disclose.

��ɫ��

��ɫ��